Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open‐label study
Semaglutide treatment resulted in significant reduction in weight and BMI in patients with obesity undergoing dialysis, while maintaining an acceptable side effect profile comparable to that of the non-dialysis population.
Authors
- Manfred Hecking (ORCID: https://orcid.org/0000-0002-8047-2395)
- Amelie Kurnikowski (ORCID: https://orcid.org/0000-0003-4282-9055)
- Sebastian Mußnig (ORCID: https://orcid.org/0000-0003-2223-2067)
- Simon Krenn (ORCID: https://orcid.org/0000-0003-0899-9085)
- Lenka Vanek
Institutions
- AIT Austrian Institute of Technology GmbH (AT)
- KfH Kuratorium für Dialyse und Nierentransplantation (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-10-07
- DOI
- https://doi.org/10.1111/dom.15967
- Citations
- 20
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 7.15
Funders
- Vienna Science and Technology Fund